Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent-Reference-Cited by-同舟云学术

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

Published:1998-08 Issue:2 Volume:70 Page:272-274
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Markman Maurie,Kennedy Alexander,Sutton Gregory,Hurteau Jean,Webster Kenneth,Peterson Gertrude,Kulp Barbara,Belinson Jerome

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference11 articles.

1. Cancer of the ovary;Cannistra;N Engl J Med,1993

2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

3. Responses to “salvage” chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population;Markman;J Clin Oncol,1992

4. Ifosfamide treatment of advanced ovarian cancer;Yazigi;Obstet Gynecol,1984

5. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results;Willemse;Cancer Chemother Pharmacol,1990

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma;Frontiers in Oncology;2021-07-21

2. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer;Obstetrics & Gynecology Science;2018

3. Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma;International Journal of Gynecologic Cancer;2016-07

4. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer;Journal of Ovarian Research;2014-04-09

5. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer;Cancer Chemotherapy and Pharmacology;2013-08-03